Peptide API subsidiary of Aurobindo Pharma with a plant near Hyderabad. Makes generic peptide APIs and runs GMP contract projects from mg to kg scale.
- Model
- CDMO
- Manufacturer?
- Yes
Etelcalcetide is a calcimimetic peptide for secondary hyperparathyroidism (Parsabiv).
4 listed companies hold an active US Type II Drug Master File for Etelcalcetide API, based in India (3), China (1). 4 have a regulator record of GMP manufacturing, and 1 carries an open FDA warning letter.
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Source: FDA Drug Master File list. Holding a DMF is a regulatory filing, not an FDA approval.
Peptide API subsidiary of Aurobindo Pharma with a plant near Hyderabad. Makes generic peptide APIs and runs GMP contract projects from mg to kg scale.
Hyderabad-based MSN Group entity holding US DMFs for 11 peptide APIs, including semaglutide and tirzepatide. MSN runs 27 plants in India, the USA and Indonesia.
Chinese peptide drug manufacturer producing APIs and finished products.
Mumbai drug maker with its own API and formulation plants in India. Holds US DMFs for 3 peptide APIs. Received an FDA CGMP warning letter in November 2026.
Companies holding active US DMFs for Etelcalcetide include Auro Peptides Ltd, MSN Life Sciences Private Ltd (MSN Group), Hybio Pharmaceutical and USV Private Limited. Other manufacturers may supply it without a US DMF.
Among listed DMF holders: India (3), China (1).
USV Private Limited has an open FDA warning letter, shown on the listing and in the FDA enforcement tracker.
No. FDA reviews a DMF when a drug application references it and does not approve DMFs on their own.